1. Home
  2. RDW vs ADPT Comparison

RDW vs ADPT Comparison

Compare RDW & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDW

Redwire Corporation

N/A

Current Price

$9.17

Market Cap

1.8B

Sector

Industrials

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$13.92

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RDW
ADPT
Founded
2020
2009
Country
United States
United States
Employees
750
N/A
Industry
Military/Government/Technical
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
RDW
ADPT
Price
$9.17
$13.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
9
Target Price
$13.71
$17.78
AVG Volume (30 Days)
12.3M
2.0M
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
$41.47
$3.98
Revenue Next Year
$21.04
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
54.77
52 Week Low
$4.87
$6.68
52 Week High
$22.25
$20.76

Technical Indicators

Market Signals
Indicator
RDW
ADPT
Relative Strength Index (RSI) 47.80 41.12
Support Level $7.94 $12.24
Resistance Level $10.26 $17.52
Average True Range (ATR) 0.78 0.69
MACD 0.01 0.01
Stochastic Oscillator 35.25 43.56

Price Performance

Historical Comparison
RDW
ADPT

About RDW Redwire Corporation

Redwire Corp is an integrated space and defense technology company focused on technologies including aerospace infrastructure, autonomous systems and multi-domain operations, leveraging digital engineering and artificial intelligence automation. The Company develops and provides mission critical solutions based on space and defense technology platform offerings for government, commercial and civil customers through both short- and long-duration projects. These include technologies and production capability for next-generation spacecraft, large space infrastructure, microgravity capabilities, combat autonomous systems, optical sensors and radio frequency payloads that provide intelligence, surveillance, and reconnaissance capabilities for U.S. and allied nations across multiple domains.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: